Gameto's Deal Worth 'Up To' $1.38 Billion Is a Big New York Biotech Exit. Read the Fine Print

NEW YORK — A big New York startup exit this fall comes from women’s health. Ferring Pharmaceuticals, the privately owned Swiss drugmaker, has signed an agreement to acquire Gameto, a New York biotech that uses cell engineering to rethink in vitro fertilization. The companies announced the deal on Oct. 27 with a value of “up to $1.3825 billion.”

Those two words, “up to,” are the most important part of the headline, and they’re worth understanding for any founder who hopes to sell a company someday.

What Gameto Built

Gameto was founded by Dr. Dina Radenkovic Turner, its CEO, and Martin Varsavsky, the founder of the fertility clinic network Inception Prelude, according to AlleyWatch. Gameto’s own company announcements carry a New York dateline.

Its lead program, Fertilo, is an in vitro maturation technology. Standard IVF typically requires about two weeks of daily hormone injections to stimulate the ovaries, BioPharma Dive explained. Fertilo instead uses stem cell-derived ovarian support cells to help eggs mature outside the body, and Gameto says the approach could shorten IVF and egg-freezing cycles to as little as three days.

Fertilo is already used in clinics in Australia and Latin America, according to AlleyWatch. In the U.S. it is still in a Phase 3 trial, with preliminary results expected in late 2026. Both companies stress that Gameto’s in vitro maturation program is investigational in the United States and has not been approved by the Food and Drug Administration. Gameto is also developing menopause therapies through a program called Ameno, which has received funding from ARPA-H, the federal health research agency.

How the Money Got There

AlleyWatch reports that Gameto raised $127 million in equity funding. That includes a $44 million Series C in August 2025 led by Overwater Ventures and a $33 million Series B in May 2024 led by Two Sigma Ventures with RA Capital Management. The investor list is long and includes Insight Partners, Lux Capital, FJ Labs and Future Ventures, plus angels such as Anne Wojcicki and Brian Armstrong.

On paper, a deal worth up to $1.38 billion is roughly 11 times the equity Gameto raised. But that’s the ceiling, not the check.

Read the Fine Print: “Up To”

The companies said the total value is “subject to development, regulatory and commercial milestones.” BioPharma Dive noted that Ferring did not disclose how much it is paying upfront. In practice, that means part of the price depends on things that haven’t happened yet. Those could include trial results, a regulatory decision or sales targets. The companies have not said what the specific milestones are.

This structure is common in biotech acquisitions, and it’s increasingly familiar elsewhere too. The terms go by different names, including milestones, earnouts and contingent payments, but the logic is the same. A buyer and seller disagree about what an unproven asset is worth, so they split the difference by paying more only if it proves itself.

For founders and early employees, the details decide what the headline is actually worth:

• The upfront amount is the only money that is certain at closing.
• Milestone definitions decide whether the rest is realistic. “Regulatory approval” for a therapy in late-stage trials is very different from an aggressive sales target years out.
• Who controls the outcome matters. After closing, the buyer usually runs the program. Sellers should know what effort the buyer has promised to make toward each milestone.
• Timing and taxes change the math. Money paid years later is worth less today, and the tax treatment of contingent payments can be complicated. That’s a question for an advisor, not a blog post.

None of this is a knock on Gameto’s deal; we don’t know its terms beyond what the companies announced. It’s a reminder that “up to” deserves the same scrutiny as a valuation in a term sheet.

Why It Matters for New York

The deal is good news for a city that has worked to build a life-sciences scene alongside its software startups. A sale by a New York-founded biotech to a global strategic buyer shows investors that local companies can reach an exit. It may also send experienced operators back into the ecosystem to start or fund the next company.

It’s also a signal about women’s health, a category founders have long said was underfunded. “This is a defining moment for Gameto and for our mission to transform reproductive health,” Turner said in the joint announcement. Ferring CEO Jean-Frédéric Paulsen said the company saw “an opportunity to advance new approaches in fertility care and reach more patients worldwide.”

What Happens Now

The deal still has to close and remains subject to customary conditions, and the two companies will operate independently until then. The next real test for the “up to” in the price is the U.S. Phase 3 data. When results arrive, they’ll show how much of that $1.38 billion is likely to be paid.

Entrepreneurs Of New York is an independent publication and is not affiliated with Gameto or Ferring. This article is not medical or financial advice.